Monday, the FDA’s Office of Prescription Drug Promotion posted a new untitled letter dated Sept. 23 and addressed to AstraZeneca. More: FDA takes issue with AstraZeneca TV ad, citing 'misleading impression' of Farxiga indications Source: fierce
read moreCytokinetics is following in the footsteps of Bristol Myers Squibb as it prepares to try to wrest control of the heart disease market away from the Big Pharma. About a year after BMS backed an American Heart Association initiative, Cytokinetics
read more
New ONE BioHub facility expands clinical trial access and strengthens Scotland’s brain health innovation More: Scottish Brain Sciences opens new Alzheimer’s research centre in Aberdeen Source: News
read more
New treatment option for spinal muscular atrophy moves closer to EU approval More: High dose nusinersen regimen receives positive CHMP opinion Source: News
read moreBiogen has had two years to gear up for the impending launch of Sandoz’s biosimilar Tyruko, which has now hit the U.S. market after earning FDA approval in 2023. More: After delay, Sandoz's biosimilar Tyruko launches in US to pressure
read moreDays after joining its fellow GLP-1 giant, Eli Lilly, in coming to agreements with the Trump administration to slash the costs of their uber-popular weight loss meds in the U.S., Novo Nordisk has pulled back the curtain on its new
read more© 1994 - 2026 B.M. Pharmaceuticals